AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted treatment for the same rare immune disease.
Archives for October 29, 2024
CRO NovAliX teams with Bruker to advance drug development
In a move set to transform drug discovery, CRO NovAliX has partnered with Bruker, a leader in scientific instruments, through a strategic investment aimed at enhancing drug development success rates.
Aldevron’s Anu Codaty on passion, leadership, and innovation
Anu Codaty, VP of global marketing and strategy at Aldevron, is blazing trails in biotech, inspired by a family legacy in medicine and driven to create life-changing therapies.
EC approves Janssen’s Darzalex-SC combo for multiple myeloma
New Darzelex SC quadruplet regimen approved by European Commission for newly diagnosed multiple myeloma patients.
Ottimo Pharma emerges from stealth mode with prominent leadership and a promising cancer therapy
Backed by Medicxi, Ottimo Pharma is going to be working on Jankistomig and is headed by David Epstein